ReviewJournal of stroke2021
Development and Testing of Thrombolytics in Stroke.
Review in Journal of stroke, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Meta-analysis of outcomes following intravenous thrombolysis in patients with ischemic stroke on direct oral anticoagulants.BMC neurology · 2023Pooled it
- Rapid screening of staphylokinase protein variants using an unpurified cell-free expression system.FEBS open bio · 2026Article
- Thrombolytic proteins profiling: High-throughput activity, selectivity, and resistance assays.FEBS open bio · 2026Article
- Inhibiting Monocyte Migration Reduces Arterial Thrombosis and Facilitates Thrombolysis.Stroke · 2025Article
- Stem Cell Therapy Approaches for Ischemia: Assessing Current Innovations and Future Directions.International journal of molecular sciences · 2025Review
- Response surface methodology to optimize theJournal of food science and technology · 2025Article
- Acupuncture as adjunctive therapy for acute cerebral infarction: a randomized clinical trial.Frontiers in neurology · 2025Article
- Review
- Thrombolysis for acute ischaemic stroke: development and update.Brain communications · 2025Review
- Nanomedicine in Management of Cerebral Infarction and Brain Cancer: Role of Inflammation.Current medicinal chemistry · 2025Review
- Intravenous Thrombolysis with Urokinase for Acute Ischemic Stroke.Brain sciences · 2024Review
- Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment.Biomedicines · 2024Review
- Article
- Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment.PloS one · 2024Article
- Towards a biomarker for acute arterial thrombosis using complete blood count and white blood cell differential parameters in mice.Scientific reports · 2023Article
- In Silico Study of Different Thrombolytic Agents for Fibrinolysis in Acute Ischemic Stroke.Pharmaceutics · 2023Article
- Computer-aided engineering of staphylokinase toward enhanced affinity and selectivity for plasmin.Computational and structural biotechnology journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
Despite recent advances in recanalization therapy, mechanical thrombectomy will never be a treatment for every ischemic stroke because access to mechanical thrombectomy is still limited in many countries. Moreover, many ischemic strokes are caused by occlusion of cerebral arteries that cannot be reached by intra-arterial catheters. Reperfusion using thrombolytic agents will therefore remain an important therapy for hyperacute ischemic stroke. However, thrombolytic drugs have shown limited efficacy and notable hemorrhagic complication rates, leaving room for improvement. A comprehensive understanding of basic and clinical research pipelines as well as the current status of thrombolytic therapy will help facilitate the development of new thrombolytics. Compared with alteplase, an ideal thrombolytic agent is expected to provide faster reperfusion in more patients; prevent re-occlusions; have higher fibrin specificity for selective activation of clot-bound plasminogen to decrease bleeding complications; be retained in the blood for a longer time to minimize dosage and allow administration as a single bolus; be more resistant to inhibitors; and be less antigenic for repetitive usage. Here, we review the currently available thrombolytics, strategies for the development of new clot-dissolving substances, and the assessment of thrombolytic efficacies in vitro and in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.